DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma

Information source: Fudan University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Endometrial Atypical Hyperplasia; Endometrial Adenocarcinoma

Intervention: Megestrol acetate and metformin (Drug); Megestrol acetate (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: Xiaojun Chen

Official(s) and/or principal investigator(s):
Xiaojun Chen, PhD, Study Chair, Affiliation: Obstetrics & Gynecology Hospital of Fudan University

Overall contact:
Xiaojun Chen, PhD, Phone: 862163455050, Email: cxjlhjj@163.com


The purpose of this study is to see if megestrol acetate plus metformin will be more effective in returning the endometrial tissue to a normal state than megestrol acetate alone in patients with endometrial atypical hyperplasia or early stage endometrial adenocarcinoma.

Clinical Details

Official title: Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Pathological response rate

Secondary outcome:

Toxicity evaluation

Rate of relapse

Rate of pregnancy

Detailed description: After diagnosed of endometrial atypical hyperplasia(EAH) or type I endometrial cancer(EC) by dilatation and curettage (D&C) or hysteroscopy, patients will be enrolled. Age, waist circumstances, blood pressure, basic history of infertility, blood pressure, serum lipid level and side effects will be collected. Blood tests, including triglycerides, high density lipoprotein-cholesterol, fasting blood glucose, liver and kidney function will be performed before treatment to evacuate their metabolic conditions. Patients are randomized to 1 of 2 treatment groups. Patients will receive metformin 500 mg by mouth third daily and megestrol acetate 150 mg by mouth daily for 3 months on Arm I. Patients will receive megestrol acetate 150 mg PO daily for 3 months on Arm II. Then an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded. For patients with EAH, complete response (CR) is defined as the reversion of endometrial atypical hyperplasia to proliferative or secretory endometrium; partial response (PR) is defined as regression to simple or complex hyperplasia without atypia; no response (NR) is defined as the persistence of the disease; and progressive disease (PD) is defined as the appearance of endometrial cancer in patients. EAH after treatment will be defined as PR in patients with EC. Continuous therapies will be needed in PR, NR or PD. After completion of study treatment, 3 months of maintenance treatment will be recommended for patients with CR, and they will be followed up for 2 years. In addition, we've already had a pilot study in 19 patients primarily diagnosed of endometrial atypical hyperplasia from August 2012 to April 2013. 10 patients were in Arm I and 9 patients were in Arm II. Metabolic syndrome were evaluated among all subjects. After treatment, megestrol acetate plus metformin worked better than megestrol acetate alone. But two arms showed no difference in NR patients, which may suggest metformin just worked as an antitumor drug more than an insulin sensitizer. More supportive researches are needed to verify it.


Minimum age: 18 Years. Maximum age: 45 Years. Gender(s): Female.


Inclusion Criteria:

- Be between the ages of 18-45 years old

- Primarily have a confirmed diagnosis of endometrial atypical hyperplasia based upon

D&C or hysteroscopy

- OR primarily have a confirmed diagnosis of endometrial adenocarcinoma(G1, low

tumor grade), based upon D&C or hysteroscopy, and three MRI parameters shows there's no myometrial invasion, extension beyond corpus, or enlarged lymph nodes

- Have a desire for remaining reproductive function or uterus

- Need to be able to undergo correlative treatment and follow-up

Exclusion Criteria:

- Have a history of serious liver or renal dysfunction

- Have a confirmed diagnosis of malignant tumor in genital system

- Have taken oral contraceptive or other medicine for the treatment of endometrial

hyperplasia in the past 6 months

- Ask for removal of the uterus or other conservative treatment

- serum CA-125 > 35 Um/L

Locations and Contacts

Xiaojun Chen, PhD, Phone: 862163455050, Email: cxjlhjj@163.com

Fudan University Shanghai Cancer Center, Shanghai, Shanghai 200032, China; Recruiting
Huaying Wang, PhD, Email: huaying_wang@yahoo.com

Obstetrics and Gynecology Hospital, Fudan University, Shanghai, Shanghai 200011, China; Recruiting
Xiaojun Chen, PhD, Phone: 862163455055, Email: cxjlhjj@163.com
Bingyi Yang, BD, Phone: 862163455055, Email: xiaomihaoku@163.com
Bingyi Yang, BD, Principal Investigator

Shanghai Changning Maternity & Infant Health Hospital, Shanghai, Shanghai, China; Recruiting
Chengbin Ma, Email: machenbin@sohu.com

Shanghai Sixth People's Hospital, Shanghai, Shanghai, China; Recruiting
Yincheng Teng
Zhihong Ai, Email: ai_zhihong@126.com

Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China; Recruiting
Jianqing Zhu, Phone: +86-0571-88122222
Huafeng Shou, Phone: +86-0571-88122222, Email: hfshou@126.com

Additional Information

Starting date: October 2013
Last updated: April 6, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017